Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tajixanthone is a naturally occurring xanthone derivative isolated from the mycelia of endophytic fungi, most notably *Emericella variecolor*, which is found in the leaves of *Croton oblongifolius*. It belongs to a class of secondary metabolites known for their diverse biological activities, particularly their potential as antineoplastic agents. Research indicates that tajixanthone and its derivatives, such as tajixanthone hydrate and tajixanthone methanoate, possess significant cytotoxic properties against various human tumor cell lines, including gastric, colon, breast, hepatocarcinoma, and lung carcinomas. In preclinical studies, the antitumor activity of these xanthones has been compared to standard chemotherapeutic agents like doxorubicin hydrochloride, with some derivatives showing comparable potency and selectivity against specific cancer types like gastric and breast carcinomas.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tajixanthone.